- Home
- CCEC vs MYGN Comparison
CCEC vs MYGN Comparison
Compare CCEC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- MYGN
- Stock Information
- Founded
- CCEC 2007
- MYGN 1991
- Country
- CCEC Greece
- MYGN United States
- Employees
- CCEC N/A
- MYGN N/A
- Industry
- CCEC Marine Transportation
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CCEC Consumer Discretionary
- MYGN Health Care
- Exchange
- CCEC Nasdaq
- MYGN Nasdaq
- Market Cap
- CCEC 1.1B
- MYGN 1.3B
- IPO Year
- CCEC 2007
- MYGN 1995
- Fundamental
- Price
- CCEC $19.14
- MYGN $8.81
- Analyst Decision
- CCEC Buy
- MYGN Hold
- Analyst Count
- CCEC 2
- MYGN 15
- Target Price
- CCEC $24.00
- MYGN $21.37
- AVG Volume (30 Days)
- CCEC 13.7K
- MYGN 926.8K
- Earning Date
- CCEC 04-29-2025
- MYGN 05-06-2025
- Dividend Yield
- CCEC 3.03%
- MYGN N/A
- EPS Growth
- CCEC 20.78
- MYGN N/A
- EPS
- CCEC 2.60
- MYGN N/A
- Revenue
- CCEC $369,413,000.00
- MYGN $837,600,000.00
- Revenue This Year
- CCEC $19.13
- MYGN $2.97
- Revenue Next Year
- CCEC $20.93
- MYGN $8.37
- P/E Ratio
- CCEC $162.75
- MYGN N/A
- Revenue Growth
- CCEC 2.45
- MYGN 11.21
- 52 Week Low
- CCEC $14.45
- MYGN $8.70
- 52 Week High
- CCEC $20.26
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- MYGN 27.71
- Support Level
- CCEC N/A
- MYGN $9.68
- Resistance Level
- CCEC N/A
- MYGN $10.30
- Average True Range (ATR)
- CCEC 0.00
- MYGN 0.54
- MACD
- CCEC 0.00
- MYGN -0.00
- Stochastic Oscillator
- CCEC 0.00
- MYGN 6.57
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.